|
1
|
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
|
N Engl J Med
|
2002
|
4.89
|
|
2
|
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.
|
BMJ
|
2011
|
3.72
|
|
3
|
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.
|
HIV Med
|
2008
|
3.67
|
|
4
|
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
|
Lancet
|
2007
|
3.40
|
|
5
|
Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial.
|
BMJ
|
2012
|
2.66
|
|
6
|
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.
|
J Acquir Immune Defic Syndr
|
2010
|
2.59
|
|
7
|
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.
|
AIDS
|
2007
|
2.47
|
|
8
|
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
|
AIDS
|
2005
|
2.45
|
|
9
|
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
|
AIDS
|
2006
|
2.35
|
|
10
|
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.
|
AIDS
|
2014
|
2.27
|
|
11
|
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.
|
HIV Med
|
2012
|
2.24
|
|
12
|
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).
|
HIV Med
|
2014
|
2.18
|
|
13
|
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era.
|
Eur J Neurol
|
2010
|
2.06
|
|
14
|
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.
|
Lancet
|
2007
|
2.06
|
|
15
|
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.
|
Clin Infect Dis
|
2012
|
1.76
|
|
16
|
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies.
|
AIDS
|
2003
|
1.60
|
|
17
|
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
|
J Clin Oncol
|
2012
|
1.55
|
|
18
|
Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults.
|
J Infect
|
2010
|
1.49
|
|
19
|
Achieving compliance with the European Working Time Directive in a large teaching hospital: a strategic approach.
|
Clin Med
|
2004
|
1.49
|
|
20
|
The changing pattern of bronchoscopy in an HIV-infected population.
|
Chest
|
2002
|
1.42
|
|
21
|
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
|
Antivir Ther
|
2008
|
1.41
|
|
22
|
Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection.
|
AIDS
|
2003
|
1.41
|
|
23
|
Iatrogenic effects of group treatment for antisocial youths.
|
J Consult Clin Psychol
|
2005
|
1.41
|
|
24
|
Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse.
|
Sex Transm Infect
|
2010
|
1.40
|
|
25
|
Suicidal ideation in UK HIV clinic attenders.
|
AIDS
|
2008
|
1.31
|
|
26
|
Data linkage reduces loss to follow-up in an observational HIV cohort study.
|
J Clin Epidemiol
|
2010
|
1.26
|
|
27
|
Survival following HIV infection of a cohort followed up from seroconversion in the UK.
|
AIDS
|
2008
|
1.23
|
|
28
|
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2009
|
1.23
|
|
29
|
Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
|
Antivir Ther
|
2008
|
1.21
|
|
30
|
Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2010
|
1.20
|
|
31
|
Long-term trends in adherence to antiretroviral therapy from start of HAART.
|
AIDS
|
2010
|
1.17
|
|
32
|
Comparative evaluation of the ExaVir Load version 3 reverse transcriptase assay for measurement of human immunodeficiency virus type 1 plasma load.
|
J Clin Microbiol
|
2009
|
1.15
|
|
33
|
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.
|
AIDS
|
2008
|
1.11
|
|
34
|
The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008.
|
PLoS One
|
2011
|
1.09
|
|
35
|
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?
|
AIDS
|
2009
|
1.09
|
|
36
|
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
|
AIDS
|
2008
|
1.07
|
|
37
|
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.
|
Haematologica
|
2009
|
1.07
|
|
38
|
Caring for women living with HIV: gaps in the evidence.
|
J Int AIDS Soc
|
2013
|
1.07
|
|
39
|
Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
|
AIDS
|
2010
|
1.05
|
|
40
|
Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity.
|
AIDS Care
|
2008
|
1.05
|
|
41
|
What factors are associated with patient self-reported health status among HIV outpatients? A multi-centre UK study of biomedical and psychosocial factors.
|
AIDS Care
|
2012
|
1.04
|
|
42
|
Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.
|
J Bone Miner Res
|
2013
|
1.03
|
|
43
|
Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors.
|
PLoS One
|
2011
|
1.02
|
|
44
|
Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
|
AIDS
|
2008
|
1.02
|
|
45
|
Patient understanding of moles and skin cancer, and factors influencing presentation in primary care: a qualitative study.
|
BMC Fam Pract
|
2010
|
1.00
|
|
46
|
Economic analysis of combined endoscopic and endobronchial ultrasound in the evaluation of patients with suspected non-small cell lung cancer.
|
Lung Cancer
|
2009
|
0.99
|
|
47
|
Successive switching of antiretroviral therapy is associated with high psychological and physical burden.
|
Int J STD AIDS
|
2007
|
0.98
|
|
48
|
Rising population cost for treating people living with HIV in the UK, 1997-2013.
|
PLoS One
|
2010
|
0.96
|
|
49
|
The 'Antiretrovirals, Sexual Transmission Risk and Attitudes' (ASTRA) study. Design, methods and participant characteristics.
|
PLoS One
|
2013
|
0.96
|
|
50
|
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
|
J Antimicrob Chemother
|
2010
|
0.96
|
|
51
|
Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy.
|
AIDS
|
2004
|
0.96
|
|
52
|
Novel method for visualizing and modeling the spatial distribution of neural stem cells within intracranial glioma.
|
Neuroimage
|
2007
|
0.96
|
|
53
|
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
|
AIDS
|
2005
|
0.95
|
|
54
|
Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial.
|
AIDS
|
2015
|
0.95
|
|
55
|
Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
|
J Med Virol
|
2007
|
0.95
|
|
56
|
CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy.
|
AIDS
|
2002
|
0.94
|
|
57
|
Impaired antigen-specific CD4(+) T lymphocyte responses in cavitary tuberculosis.
|
Tuberculosis (Edinb)
|
2008
|
0.94
|
|
58
|
Introduction to late presentation for HIV treatment in Europe.
|
Antivir Ther
|
2010
|
0.94
|
|
59
|
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.
|
J Acquir Immune Defic Syndr
|
2008
|
0.93
|
|
60
|
Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006.
|
PLoS One
|
2011
|
0.93
|
|
61
|
Protocol for the MoleMate UK Trial: a randomised controlled trial of the MoleMate system in the management of pigmented skin lesions in primary care [ISRCTN 79932379].
|
BMC Fam Pract
|
2010
|
0.92
|
|
62
|
Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation.
|
Antivir Ther
|
2010
|
0.92
|
|
63
|
Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
|
J Acquir Immune Defic Syndr
|
2008
|
0.91
|
|
64
|
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.
|
AIDS
|
2007
|
0.91
|
|
65
|
Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis.
|
PLoS One
|
2011
|
0.91
|
|
66
|
Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes.
|
J Virol
|
2003
|
0.90
|
|
67
|
Mitochondrial fatty acid beta-oxidation in the retinal pigment epithelium.
|
Pediatr Res
|
2002
|
0.90
|
|
68
|
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
|
AIDS Res Hum Retroviruses
|
2010
|
0.88
|
|
69
|
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy.
|
AIDS
|
2014
|
0.87
|
|
70
|
Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
|
Antivir Ther
|
2004
|
0.87
|
|
71
|
Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
|
Intervirology
|
2012
|
0.87
|
|
72
|
Clinical and behavioural aspects of aging with HIV infection.
|
Psychol Health Med
|
2009
|
0.87
|
|
73
|
Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men.
|
J Acquir Immune Defic Syndr
|
2014
|
0.87
|
|
74
|
Behavioral surveillance study: sexual risk taking behaviour in UK HIV outpatient attendees.
|
AIDS Behav
|
2012
|
0.86
|
|
75
|
The impact of HIV drug resistance testing on changes to treatment.
|
AIDS
|
2011
|
0.84
|
|
76
|
Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providers.
|
Sex Transm Infect
|
2012
|
0.83
|
|
77
|
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.
|
AIDS
|
2014
|
0.82
|
|
78
|
Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification.
|
PLoS Med
|
2012
|
0.82
|
|
79
|
Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.
|
BMC Infect Dis
|
2014
|
0.82
|
|
80
|
Liquid chromatographic-electrospray mass spectrometric determination of 1-methyl-4-phenylpyridine (MPP+) in discrete regions of murine brain.
|
Toxicol Mech Methods
|
2010
|
0.82
|
|
81
|
Diagnostic analysis of veterinary dried blood spots for toxic heavy metals exposure.
|
J Anal Toxicol
|
2013
|
0.81
|
|
82
|
Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
|
J Infect Dis
|
2009
|
0.81
|
|
83
|
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.
|
J Antimicrob Chemother
|
2013
|
0.81
|
|
84
|
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
|
Antivir Ther
|
2006
|
0.81
|
|
85
|
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.
|
Antivir Ther
|
2011
|
0.81
|
|
86
|
Introduction: promoting concept driven teaching strategies in biochemistry and molecular biology.
|
Biochem Mol Biol Educ
|
2013
|
0.81
|
|
87
|
Coronary artery disease and HIV; getting to the HAART of the matter.
|
Int J Cardiol
|
2012
|
0.81
|
|
88
|
Reconstitution of herpes simplex virus-specific T cell immunity in HIV-infected patients receiving highly active antiretroviral therapy.
|
J Infect Dis
|
2006
|
0.80
|
|
89
|
Factors influencing lopinavir and atazanavir plasma concentration.
|
J Antimicrob Chemother
|
2010
|
0.80
|
|
90
|
Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks.
|
HIV Clin Trials
|
2003
|
0.80
|
|
91
|
Does severity predict distress? The relationship between subjective and objective measures of appearance and psychological adjustment, during treatment for facial lipoatrophy.
|
Body Image
|
2007
|
0.80
|
|
92
|
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
|
J Antimicrob Chemother
|
2004
|
0.79
|
|
93
|
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
|
Patient
|
2015
|
0.79
|
|
94
|
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.
|
PLoS One
|
2012
|
0.79
|
|
95
|
End-stage kidney disease and kidney transplantation in HIV-positive patients: an observational cohort study.
|
J Acquir Immune Defic Syndr
|
2014
|
0.78
|
|
96
|
Gender and mental health aspects of living with HIV disease and its longer-term outcomes for UK heterosexual patients.
|
Women Health
|
2012
|
0.78
|
|
97
|
The need for data on women living with HIV in Europe.
|
Antivir Ther
|
2013
|
0.78
|
|
98
|
The cost-effectiveness of a novel SIAscopic diagnostic aid for the management of pigmented skin lesions in primary care: a decision-analytic model.
|
Value Health
|
2013
|
0.77
|
|
99
|
A family medicine training collaborative in early abortion.
|
Fam Med
|
2007
|
0.77
|
|
100
|
Detecting HIV-1 superinfection by pol gene population sequencing among untreated HIV-1-infected men who experience sudden rises in plasma HIV-1 RNA load.
|
AIDS
|
2011
|
0.77
|
|
101
|
Rapid and reliable identification of ionophore antibiotics in feeds by liquid chromatography-tandem mass spectrometry.
|
J Vet Diagn Invest
|
2011
|
0.77
|
|
102
|
Examination of Eurasian griffon vultures (Gyps fulvus fulvus) in Israel for exposure to environmental toxicants using dried blood spots.
|
Arch Environ Contam Toxicol
|
2011
|
0.77
|
|
103
|
Competencies in pulmonary procedures.
|
Chest
|
2004
|
0.77
|
|
104
|
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?
|
J Infect Dis
|
2012
|
0.76
|
|
105
|
Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy.
|
AIDS
|
2016
|
0.76
|
|
106
|
Biomarkers to monitor safety in people on art and risk of mortality.
|
J Acquir Immune Defic Syndr
|
2012
|
0.76
|
|
107
|
Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study.
|
HIV Clin Trials
|
2003
|
0.76
|
|
108
|
Resolution of azole-resistant oesophageal candidiasis in an AIDS patient after treatment with caspofungin.
|
AIDS
|
2003
|
0.75
|
|
109
|
Response to "Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?" by Hill.
|
AIDS
|
2006
|
0.75
|
|
110
|
British HIV Association national audit on the management of patients co-infected with tuberculosis and HIV.
|
Clin Med
|
2011
|
0.75
|
|
111
|
Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing.
|
AIDS
|
2002
|
0.75
|
|
112
|
Commentary: Biochemistry and molecular biology educators launch national network.
|
Biochem Mol Biol Educ
|
2010
|
0.75
|
|
113
|
Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism.
|
J Antimicrob Chemother
|
2008
|
0.75
|
|
114
|
Predicting antiretroviral drug resistance from the latest or the cumulative genotype.
|
Antivir Ther
|
2011
|
0.75
|
|
115
|
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.
|
J Acquir Immune Defic Syndr
|
2009
|
0.75
|
|
116
|
Pseudomonal sepsis with subcutaneous nodules in an HIV-infected individual with high CD4 counts.
|
J Infect
|
2005
|
0.75
|
|
117
|
Facial atrophy in HIV-related fat redistribution syndrome: a plastic surgical perspective on treatment options and a look to the future.
|
Int J STD AIDS
|
2006
|
0.75
|
|
118
|
Pneumocystis pneumonia revisited: delayed diagnosis in an HIV infected individual with high blood and low lung CD4 T cell counts.
|
J Infect
|
2006
|
0.75
|
|
119
|
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.
|
AIDS
|
2017
|
0.75
|
|
120
|
Determination of methomyl in the stomach contents of baited wildlife by gas chromatography-mass spectrometry.
|
J Vet Diagn Invest
|
2013
|
0.75
|
|
121
|
Rapid quantification of ionophores in feeds by liquid chromatography-tandem mass spectrometry.
|
J Vet Diagn Invest
|
2011
|
0.75
|
|
122
|
Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles.
|
Epidemiology
|
2019
|
0.75
|
|
123
|
Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
|
Pharmacoeconomics
|
2010
|
0.75
|